Full Text (PDF)
Original Article

Analysis of Hepcidin, Ferritin, CRP and Iron Levels in ESRD Patients and Their Correlation in CKD-4 & 5 Stages with/without Iron Intake

Praveen Kumar Kolla , Rakesh Y.* , Varaprasada Rao K.* , Praveen Kumar Kolla*

Author Information

Licence:




Urology, Nephrology and Andrology International 1(1):p 21-26, January - June 2016. | DOI:

How Cite This Article:


Timeline

Received : N/A         Accepted : N/A          Published : N/A

Abstract

 Inflammation interferes with iron utilization in chronic kidney disease through hepcidin. In our study, iron levels, ferritin, CRP and hepcidin levels were analyzed in newly diagnosed end-stage renal disease (ESRD) patients. A total of 50 ESRD patients and 5 healthy controls were studied. 40 recently detected ESRD patients on hemodialysis and 10 patients with Stage 4 CKD not received HD or parenteral iron, 22 out of 40 ESRD patients had already received prior parenteral iron or blood products. The ESRD patients had a significantly lower estimated albumin; and higher transferrin saturation (TSAT) and raised serum ferritin and Hepcidin levels. Hepcidin levels correlated significantly with Ferritin levels. Whereas ferritin levels correlated significantly with CRP levels. There have been elevated serum hepcidin levels in ESRD patients more in those receiving Iron therapy. High hepcidin levels could explain the functional iron deficiency. Larger randomized multicenter studies could throw more light on the diagnostic and therapeutic potentials of using Hepcidin-25 levels in regular practice.


Keywords: Chronic Kidney Disease; Hepcidin; CRP; Hemodialysis.


References

No records found.


About this article


Cite this article


Licence:




Received Accepted Published
N/A N/A N/A

DOI:

Keywords


Article Level Metrics

Last Updated

Thursday 30 July 2026, 07:15:36 (IST)


500

Accesses

2
140
00

Citations


NA
NA
NA

Download citation


Article Keywords


Keyword Highlighting

Highlight selected keywords in the article text.


Timeline


Received N/A
Accepted N/A
Published N/A

licence



Access this article



Share